Bayer/€BAYN

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Bayer

Bayer AG, operating under the ticker BAYN, is a global enterprise with core competencies in the life sciences fields of healthcare and agriculture. Founded in 1863, the company is headquartered in Leverkusen, Germany, and operates in several sectors, including Pharmaceuticals, Consumer Health, Crop Science, and Animal Health. Bayer is known for developing new molecules for use in innovative products and solutions to improve the health of humans, animals, and plants.

Ticker

€BAYN

Primary listing

XETRA

Industry

Pharmaceuticals

Employees

90,885

ISIN

DE000BAY0017

Bayer Metrics

BasicAdvanced
€27B
-
-€3.32
0.98
€0.11
0.40%

What the Analysts think about Bayer

Analyst ratings (Buy, Hold, Sell) for Bayer stock.

Bulls say / Bears say

Bayer's first-quarter adjusted EBITDA declined by only 7.4% to €4.09 billion, surpassing market expectations of €3.75 billion, indicating resilience in its financial performance. (reuters.com)
The company's pharmaceuticals division is projected to achieve sales growth and EBITDA margin at the upper end of its target range for 2025, reflecting strong performance in new prescription drugs. (reuters.com)
Bayer has implemented significant cost-cutting measures, including reducing 2,000 full-time positions in the first quarter of 2025, aiming for annual cost savings of €2 billion from 2026. (reuters.com)
Bayer faces ongoing legal challenges related to its glyphosate-based weedkiller, with the U.S. Supreme Court seeking the solicitor general's opinion in a case that could result in substantial liabilities. (reuters.com)
The company has sought shareholder approval to raise fresh equity capital worth €875 million, potentially diluting existing shares and indicating financial strain due to litigation costs. (reuters.com)
Bayer's stock has experienced significant volatility, with shares dropping 4.2% following news of the Supreme Court's request, reflecting investor concerns over legal uncertainties. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.

Bayer Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Bayer Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €BAYN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs